AGP Picks
View all

AGP Executive Report

Your go-to archive of top headlines, summarized for quick and easy reading.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

Teen Health: Cannabis appeared in 84% of substance-related emergency or hospital encounters among 16- to 18-year-olds in a WashU study. That does not mean cannabis caused the visit; it appeared somewhere in patients’ records. Heart Risks: A US survey analysis presented at an American Heart Association meeting linked cannabis use with higher odds of cardiovascular disease. Stroke odds were higher even among people reporting use 1–5 days a month, though the findings do not prove cause and effect. Hemp Policy: A federal ban on most hemp-derived THC products is due Dec. 11, threatening businesses and access to products some customers use for pain or sleep. Product Safety: Cyprus officials found multiple new cannabinoids in seized vape liquids, including six types in one sample, and warned that effects and combinations may be unpredictable. CBD Rules: An EU court ruling bars cannabis-derived CBD foods from using the “organic” label, adding a new constraint for CBD sellers.

Heart Health: New U.S. survey research links cannabis use with higher odds of cardiovascular disease, especially stroke. Even use on 1–5 days a month was associated with increased odds; the findings are preliminary and do not prove cannabis caused the conditions. Use Patterns: A separate study found people using cannabis in nearly every available form had higher rates of daily use and cannabis use disorder, raising questions about how consumption habits may signal risk. Hemp Rules: Hemp businesses face a Dec. 11 deadline for a federal ban on most hemp-derived THC products, while Missouri has sued retailers accused of selling intoxicating products as hemp ahead of new state restrictions. Product Safety: Cyprus officials warn that some e-cigarette liquids and herbal products contain newly identified cannabinoids with uncertain effects, including rapid heartbeat, confusion and panic. Medical Cannabis: A Birmingham chef says prescribed cannabis helped end years of night terrors and sleep problems, though his account is personal, not proof of treatment effectiveness.

Heart Health: A study of nearly 443,000 adults linked cannabis use—even one to five days a month—with 40% higher odds of reported stroke. The researchers caution that the finding shows an association, not cause and effect. Separate preliminary research also linked cannabis use to cardiovascular risk, but has not been peer-reviewed. Product Safety: Cyprus authorities found six newly identified cannabinoids in one e-cigarette liquid and warned that unlisted ingredients could trigger rapid heartbeat, confusion or panic. CBD Rules: An EU court ruled that foods containing CBD cannot be labeled organic, creating a compliance hurdle for sellers. Hemp Policy: Illinois hemp businesses sued to block a law restricting hemp-derived intoxicating products, with a hearing sought ahead of its Nov. 12 start. Medical Use: A Birmingham chef says prescribed cannabis eased his longstanding night terrors and sleep problems, while a separate review found cannabis may not improve insomnia—pointing to mixed findings on sleep benefits.

Hemp Fight: Illinois hemp businesses are seeking a court order to block a Nov. 12 state ban on intoxicating hemp products, arguing it unlawfully restricts interstate commerce. Health Watch: A study of nearly 443,000 U.S. adults found cannabis use one to five days a month was associated with 40% higher odds of reporting a prior stroke; researchers caution the findings show an association, not cause and effect. Rescheduling: The DEA and opponents have filed final briefs in the federal marijuana rescheduling hearing, with a judge’s recommendation still to come. Medical Access: Kentucky’s program has passed 30,000 cardholders, while a Massachusetts Senate bill could let veterans register for medical cannabis without a doctor’s recommendation. CBD Rules: The EU’s top court has ruled that CBD food products cannot carry an “organic” label.

Hemp Crackdown: Missouri’s attorney general filed four lawsuits against retailers accused of selling marijuana as hemp, as Illinois prepares to restrict intoxicating hemp-derived THC sales to licensed dispensaries on Nov. 12. Cannabinoid Industry: Brains Bioceutical agreed to a proposed $750 million merger that could put its cannabinoid-medicine business on Nasdaq in 2027. CBD Rules: The EU’s top court ruled that CBD food products cannot be labeled “organic,” creating a new hurdle for sellers. Medical Cannabis Access: Federal registrations were issued to hundreds of state-licensed medical cannabis dispensaries, potentially opening the door to tax breaks. Health Research: A study of nearly 450,000 U.S. adults linked cannabis use, including occasional use, to higher odds of cardiovascular disease and stroke; Oregon’s updated health guidance also weighs documented risks against potential benefits for chronic pain and seizures.

CBD Regulation: The EU’s top court ruled that CBD foods cannot carry an organic label until they receive authorization to be sold in the bloc. The decision does not declare CBD unsafe, but it adds a hurdle for sellers. Public Health: Oregon released updated guidance weighing cannabis’s potential benefits against risks, including respiratory problems and links to heart attack and stroke. New Research: A US analysis linked cannabis use with higher odds of stroke, even among occasional users; the findings show an association, not proof of cause. A UCLA study also found occasional male users reported stronger effects from smoked cannabis than women with similar use, while frequent users responded similarly. Medical Access: The Justice Department has federally registered more than 900 state-licensed medical cannabis dispensaries, opening a new pathway that so far excludes adult-use and dual-licensed operators.

Hemp Licensing: Minnesota has opened applications for 2027 hemp growing and processing licenses, due April 30. The license does not cover cannabis or hemp-derived cannabinoid products. CBD Foods: The EU’s top court says CBD foods cannot carry an organic label before they are authorized for sale as novel foods. The ruling concerns certification, not a finding that CBD is unsafe. Medical Cannabis: A UK man says prescribed cannabis helped him manage severe gout pain after other treatments fell short; access remains limited to specialist clinics, and his experience is not proof of effectiveness. Policy Watch: A new healthcare survey will assess clinicians’ knowledge of cannabinoids as federal changes affecting hemp-derived products approach. Health Research: Preliminary U.S. survey findings linked cannabis use with higher odds of a reported stroke history, but cannot show that cannabis caused strokes or establish which came first.

Sleep Research: A Cochrane review of nine trials found medical cannabis, including THC and CBD products, offered little to no meaningful improvement for insomnia; dizziness and dry mouth were among reported side effects. Heart Health: A survey of nearly 500,000 U.S. adults linked cannabis use with higher reported cardiovascular disease and stroke risk, even among occasional users. The study shows an association, not proof of cause. Teen Health: Cannabis was involved in 84% of substance-related emergency visits and hospitalizations among 16- to 18-year-olds in a Washington University study. Federal Policy: Medical marijuana rescheduling faces a Nov. 5 filing deadline as critics, including former DEA chief Asa Hutchinson, call for stronger safeguards. Separately, the DEA has registered more than 900 medical cannabis dispensaries, potentially opening access to tax benefits. Hemp Rules: A federal ban on many hemp-derived products is due in December, raising concerns for CBD businesses and consumers. Nepal: The Supreme Court ordered the government to create rules for cannabis cultivation and production for medical, scientific and industrial uses within three months; it did not legalize recreational use.

CBD Safety: Cyprus authorities warned that products seized from a CBD shop contained newly identified cannabinoids, including six in one vape liquid. They cautioned that shop sales do not guarantee safety and urged consumers to avoid products with unknown ingredients. Hemp Rules: A federal ban set for Dec. 11 could make many hemp products illegal, raising concerns for small CBD businesses and their customers. CBD and Sleep: Avecho has resumed recruitment for the final cohort of its trial of a CBD capsule for insomnia; results remain some way off. Other research has questioned whether medical cannabis reliably helps sleep, so the treatment’s benefits remain uncertain. Health Risks: A national study found cannabis was involved in 84% of substance-related emergency visits among 16- to 18-year-olds. Separately, preliminary survey findings linked even occasional use with higher reported stroke odds, but do not show that cannabis causes strokes. Massachusetts Vote: Voters rejected a repeal effort and kept recreational cannabis legal.

CBD Trial: Avecho has restarted recruitment for the final cohort of its pivotal Australian trial of a CBD capsule for insomnia; results are still some way off. Heart Health: Preliminary U.S. research linked cannabis use on 1–5 days a month to higher odds of reported stroke, but the one-time survey cannot show cannabis caused strokes. Federal Rules: A December hemp-law change could make many hemp-derived CBD products illegal. The AMA is also urging the FDA to apply drug-style safety and research standards to cannabis and other botanical products. Medical Access: The DEA has begun federally registering more than 900 medical cannabis dispensaries in seven states, potentially bringing businesses tax benefits while requiring federal compliance. Sleep Research: New coverage highlights limited scientific support for medical cannabis as a sleep aid, a caution for consumers weighing CBD or cannabis products. Teen Use: A Canadian study found nearby cannabis stores were not consistently linked to whether teens used cannabis, though greater access was tied to more frequent use among existing users during legalization’s first year.

Hemp Rules: A federal crackdown set for Dec. 11 could make many hemp-derived CBD and THC gummies, oils and drinks illegal, while products sold through state-licensed dispensaries are exempt. Veterans and other users warn the change could disrupt routines they rely on. Medical Oversight: The AMA is urging the FDA to apply rigorous safety and scientific standards to cannabis and other botanical products, as federal medical-cannabis registrations expand. Health Risks: New research links cannabis use with higher reported cardiovascular risk, especially stroke, but does not establish that cannabis causes those conditions. Health officials also report sharply rising cases of cannabis hyperemesis syndrome, marked by severe nausea and vomiting, and point to stronger THC products as a possible factor. Medical Access: The DEA has registered more than 900 medical-marijuana dispensaries, potentially easing tax burdens for some businesses.

Heart Health: New Tulane research links cannabis use with higher reported cardiovascular risk, particularly stroke, though it cannot establish cause and effect. Medical Access: The DEA registered more than 900 medical cannabis dispensaries in seven states, potentially easing tax burdens; none were in states with legal adult-use markets. CBD Regulation: A Kentucky hemp company warns upcoming federal restrictions could also affect traditional, non-intoxicating full-spectrum CBD products. Youth Use: Canadian research found nearby stores were not consistently linked to whether teens used cannabis, while a separate California study linked stronger local retail rules with lower teen use. Sleep Research: A review found surprisingly little support for medical cannabis as a sleep aid. Safety Standards: The AMA urged the FDA to apply established safety and efficacy standards to botanical products, including cannabis, and called for a special schedule to support marijuana research.

CBD Rules: A Kentucky hemp pioneer warns that federal restrictions aimed at intoxicating hemp products could also threaten traditional, non-intoxicating full-spectrum CBD. Key restrictions are scheduled to take effect Nov. 12 and Dec. 11. Product Safety: A Duke preprint reports that “tobacco-free” Choice cigarettes contained CBD, trace nicotine and a synthetic nicotine analogue; the study has not been peer-reviewed. Medical Access: The DEA registered more than 900 medical cannabis dispensaries in seven states, but none in states with regulated adult-use markets. Registration could bring tax relief and support access to treatment for chronic pain. Sleep Research: A review found research too limited to determine whether medical cannabis meaningfully improves insomnia. FDA Oversight: The American Medical Association is urging the FDA to set safety standards for botanical products, including cannabis.

Sleep Research: A major review found too little reliable evidence to show medical cannabis improves insomnia, sleep quality, sleep duration or daytime functioning, challenging its growing use as a sleep aid. Product Safety: The American Medical Association urged the FDA to apply rigorous drug-safety standards to botanical products, including cannabis, with clinical trials and post-market monitoring. Patient Access: UK artist Louis Petit, whose seizures were controlled with cannabis oil in the Netherlands, still cannot get an NHS prescription; the bankruptcy of the oil’s producer may further threaten his access. Federal Policy: The DEA has registered more than 900 medical cannabis dispensaries, a move that could bring federal protections and tax benefits to businesses. CBD and Hemp Rules: New hemp regulations are raising concerns for Vermont CBD producers and could push some THC products off shelves.

Product Safety: The American Medical Association is urging the FDA to apply rigorous drug-review standards to botanical products, including cannabis, warning that “natural” claims and social-media marketing are no substitute for clinical testing and safety monitoring. Medical Access: A UK artist whose epilepsy improved with medical cannabis still cannot get it through the NHS; now the Dutch maker of his oil has gone bankrupt, putting his supply at risk. Federal Market Shift: The DEA has registered more than 900 state-licensed medical cannabis dispensaries across seven states, a step that could open the door to tax benefits for businesses. Hemp and CBD Rules: New federal restrictions due in December could prohibit some hemp products and disrupt Vermont CBD producers. Pain Research: A study reports sustained pain relief and lower opioid use among chronic pain patients treated with medical cannabis.

Federal Access: The DEA has issued its first registrations to more than 900 state-licensed medical cannabis dispensaries in seven states, a step that could bring tax benefits to businesses and expand access to treatment. Alabama Rollout: Two more medical cannabis dispensaries are expected to open next week, bringing the state’s total to five. Massachusetts Vote: Voters decide Tuesday whether to repeal adult-use sales and home cultivation; store owners warn repeal would also undo the market’s safety rules. Hemp Policy: Looming federal restrictions could reshape the hemp market, with Vermont CBD producers among those facing disruption. Sleep Research: A 35-year study raises doubts about cannabis as a sleep aid, adding to questions about using it to fall asleep.

Federal Cannabis Access: The DEA has registered more than 900 medical cannabis dispensaries in seven states—the first federal approvals under the new Schedule III framework. Nearly 7,000 businesses have applied, but registrations come with federal rules, and unregistered operators face a Nov. 29 deadline to keep sales within the system. Sleep Research: A 35-year study found cannabis use was linked to poorer sleep measured by monitors, despite users not reporting worse sleep. Pain Care: A separate study reported sustained pain relief and reduced opioid use among chronic pain patients receiving medical cannabis treatment. Hemp Rules: Proposed federal changes could restrict some hemp-derived products, while a congressional bill would add import tariffs and testing requirements, raising concerns for CBD businesses and consumers. Youth Use: Canadian research covering more than 419,000 student responses found nearby cannabis stores were not consistently linked to whether teens used cannabis, though access was associated with more frequent use among existing users early after legalization.

Federal Access: The DEA has registered its first 900-plus state-licensed medical cannabis dispensaries across seven states, a move that could unlock tax benefits. Nearly 7,000 businesses have applied; new rules require participating businesses to buy and sell within the federal system starting Nov. 29. Sleep Research: A 35-year study linked cannabis use with poorer sleep quality measured by wearable monitors, even though users did not report sleeping worse—challenging the idea that cannabis reliably helps sleep. Hemp Rules: A federal definition change set for Dec. 11 could reclassify many intoxicating hemp-derived products as marijuana, disrupting sales and consumer access. A separate bill proposes a 50% tariff on cannabinoid products imported from China and new testing requirements. Pain Care: A study of medical cannabis treatment for chronic pain reports sustained relief and lower opioid use among patients.

Pain Care: A study of chronic-pain patients reported sustained relief and reduced opioid use after medical cannabis treatment. Separately, emergency-department data found cannabis users were no more likely than nonusers to receive opioids at discharge. Heart Health: An analysis of more than 50 million hospital records found cardiovascular admissions rose in some western states after recreational cannabis legalization; the findings show an association, not proof that legalization caused the increase. CBD Oversight: Australia’s Federal Court ordered CDA Clinics QLD to pay A$6.5 million and its former director A$450,000 over unlawful medicinal-cannabis advertising, including claims about serious conditions. Hemp Rules: New restrictions due in December could push some hemp-derived THC products off shelves, while Vermont CBD producers face a rule change that may disrupt their market. Vaping Risks: Researchers warn that cannabis vapes using apps, AI and cryptocurrency rewards could encourage more use.

Medical Cannabis & Pain: A UK registry study of 3,744 chronic-pain patients found reported improvements in pain, sleep, anxiety and quality of life during medical cannabis treatment; 23% of participants taking opioids had a meaningful reduction in use by 24 months. CBD Rules: Iowa’s guide says THC-free CBD creams and compliant tinctures are generally allowed, while CBD gummies and drinks face limits; CBD vapes, smokable hemp and delta-8 products are prohibited. Workplace & CBD: New York’s state troopers’ union is suing over an officer’s firing after he tested positive for THC. He says he used CBD gummies for injury-related pain and was not impaired on duty. Federal Policy: A bill from Rep. Steve Cohen would remove marijuana from federal drug schedules and shift key classification decisions from the Justice Department to health officials.

Sign up for:

Medical Bud News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Medical Bud News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.